LawTrump Signs Bills Extending Religious Freedom Commission and ALS LawBy Helena WardNov 4, 2026, 12:54 AM UTC
HealthNFL Pledges $500,000 to Study ALS Risk in Athletes and VeteransBy Naomi CalderOct 21, 2026, 4:47 AM UTC
BusinessWave Life Sciences and Takeda Form Global Strategic Collaboration to Advance Therapies for Central Nervous System DisordersBy Nasdaq OMXFeb 20, 2018, 12:01 PM UTC
BusinessQ Therapeutics Announces Research Collaboration With REPROCELLBy Nasdaq OMXDec 13, 2017, 12:00 PM UTC
BusinessPreclinical Data Supporting Wave Life Sciences ALS and FTD Programs Presented at 28th International Symposium on ALS/MNDBy Nasdaq OMXDec 11, 2017, 12:00 PM UTC
BusinessVoyager Therapeutics Reports Second Quarter 2017 Financial Results and Corporate HighlightsBy Nasdaq OMXAug 8, 2017, 11:05 AM UTC
BusinessCytokinetics Announces Start of FORTITUDE-ALS, a Phase 2 Clinical Trial of CK-2127107 in Patients With Amyotrophic Lateral SclerosisBy Nasdaq OMXJul 27, 2017, 11:30 AM UTC
